GNF2133 是一种有效的、选择性的、具有口服活性的DYRK1A抑制剂，对 DYRK1A 和 GSK3β 的IC50分别为 0.0062、>50 μM。GNF2133 对大鼠和人原代 β 细胞具有良好的增殖能力和功效。GNF2133 显著提高葡萄糖处理能力并增加胰岛素分泌。GNF2133 具有研究1型糖尿病的潜力。
| 生物活性 | GNF2133 is a potent, selective and orally activeDYRK1Ainhibitor withIC50s of 0.0062, >50 μM for DYRK1A and GSK3β, respectively. GNF2133 shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 significantly improves glucose disposal capacity and increasesinsulinsecretion. GNF2133 has the potential for the research of type 1 diabetes[1]. |
| IC50& Target[1] | DYRK1 | DYRK1A 0.0062 μM (IC50) | GSK3β >50 μM (IC50) |
|
体内研究
(In Vivo) | GNF2133 (30 mg/kg; p.o.) shows good oral absorption with oral bioavailability of 22.3%[1].
GNF2133 (30 mg/kg; p.o.; once a day for 5 days) shows the ability to proliferate β-cells in vivo[1].
GNF2133 (3, 10, 30 mg/kg) significantly improves glucose disposal capacity and increased insulin secretion in RIP-DTA mice[1].
Pharmacokinetic Parameters of GNF2133 in CD-1 mice[1].
| plasma (iv) | plasma (po) | pancreas (po) | | CL (mL/min/kg) | 23.5 | / | / | | Vss (L/kg) | 11 | / | / | | AUC (h·nM) | 3268 | 10974 | 144420 | | Cmax(nM) | 1977 | 1675 | 13319 | | tmax<(h) | 0.03 | 3.0 | 3.0 | | Clast(nM) | 36.6 | 19 | 1324 | | t1/2<(h) | 6.6 | 3.4 | 6.6 | |
| F (%) | / | 22.3 | / | |
CD-1 mice; 30 mg/kg; p.o. [1].
| Animal Model: | CD-1 mice[1] | | Dosage: | 30 mg/kg | | Administration: | P.o. | | Result: | Showed good oral absorption and moderate plasma exposure with oral bioavailability of 22.3%. |
| Animal Model: | Wistar Han rat[1] | | Dosage: | 30 mg/kg (0.5% methylcellulose + Tween-80) | | Administration: | P.o.; once a day for 5 days | | Result: | Increased cyclin D1 levels and overall cell density, and increased in cell proliferation marker Ki67 and insulin. |
| Animal Model: | Diphtheria toxin A (RIP-DTA) mice[1] | | Dosage: | 3, 10, 30 mg/kg (20 mg/kg doxycycline (Dox) for 5 days) | | Administration: | P.o., once a day for 35 days | | Result: | Significantly improves glucose disposal capacity and increased insulin secretion. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | 4°C | 2 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: DMSO : 4 mg/mL(9.21 mM;ultrasonic and warming and heat to 60℃) 配制储备液 | 1 mM | 2.3013 mL | 11.5067 mL | 23.0134 mL | | 5 mM | 0.4603 mL | 2.3013 mL | 4.6027 mL | | 10 mM | --- | --- | --- |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 |
m.cnreagent.com